Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ilacirnon. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 known ✓ | P41597 | 12/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.84 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 3/20 | 0.42 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ilacirnon SCHEMBL31378455 | 1.00 | CCR2 (1.00) | CCR2CYP3A4CYP2C9JAK1BRAF | |
| Ilacirnon SCHEMBL127113 | 1.00 | CCR2 (1.00) | CCR2CYP3A4CYP2C9JAK1BRAF | |
| Ilacirnon SCHEMBL125684 | 1.00 | CCR2 (1.00) | CCR2CYP3A4CYP2C9JAK1BRAF | |
| Ilacirnon SCHEMBL30231013 | 1.00 | CCR2 (1.00) | CCR2CYP3A4CYP2C9JAK1BRAF | |
| Ilacirnon SCHEMBL125683 | 0.99 | CCR2 (0.98) | CCR2CYP3A4CYP2C9JAK1BRAF | |
| SCHEMBL1188630 | 0.92 | CYP3A4 (0.84) | CCR2CYP3A4CYP2C9JAK1BRAF | |
| SCHEMBL128785 | 0.92 | CYP2C9 (1.00) | CCR2CYP3A4CYP2C9JAK1 | |
| SCHEMBL127931 | 0.90 | CCR2 (0.81) | CCR2CYP3A4CYP2C9BRAFTNNI3K | |
| SCHEMBL12594931 | 0.90 | CCR2 (0.81) | CCR2CYP3A4CYP2C9JAK1BRAF | |
| SCHEMBL130501 | 0.89 | CCR2 (0.81) | CCR2CYP3A4CYP2C9JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 405 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260007778-A1 | METHODS FOR TREATING AND DIAGNOSING BLINDING EYE DISEASES | TRANSLATUM MEDICUS INC (CA) | 2026-01-08 | — | — | US | claimed |
| EP-4662203-A1 | BINDARIT CONJUGATES, COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES OR DISORDERS | Translatum Medicus Inc. (CA) | 2025-12-17 | — | — | EP | claimed |
| US-20250352511-A1 | METHODS OF TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH ATRASENTAN | CHINOOK THERAPEUTICS INC (US) | 2025-11-20 | — | — | US | claimed |
| US-20250339520-A1 | COMPOSITIONS AND METHODS FOR USE IN KRAS-TARGETED THERAPIES FOR THE TREATMENT OF CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2025-11-06 | — | — | US | claimed |
| US-20250290127-A1 | Method And Kit For CCR2 Expression Profiling And Disease Stratification | Plumeria Therapeutics, Inc. | 2025-09-18 | — | — | US | claimed |
| CN-113939295-B | Pyridazinones and methods of use thereof | 金翅雀生物公司 | 2025-05-16 | — | — | CN | claimed |
| EP-4525857-A1 | METHODS OF TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH ATRASENTAN | Chinook Therapeutics, Inc. (US) | 2025-03-26 | — | — | EP | claimed |
| CN-119325377-A | Method for treating focal segmental glomerulosclerosis with atrasentan | 奇努克治疗公司 | 2025-01-17 | — | — | CN | claimed |
| EP-3773563-B1 | PRODRUGS OF FUSED-BICYCLIC C5AR ANTAGONISTS | CHEMOCENTRYX INC (US) | 2024-10-16 | — | — | EP | claimed |
| US-20240325565-A1 | COMBINATION TREATMENT FOR SOLID TUMORS INCLUDING A STING AGONIST AND A CCR2 ANTAGONIST | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2024-10-03 | — | — | US | claimed |
| EP-4117707-A1 | SINGLE-ARM ACTRIIA AND ACTRIIB HETEROMULTIMERS AND METHODS FOR TREATING RENAL DISEASES OR CONDITIONS | Acceleron Pharma Inc. (US) | 2023-01-18 | — | — | EP | claimed |
| CN-115515618-A | Single-arm ActRIIA and ActRIIB heteromultimers and methods for treating kidney diseases or disorders | 阿塞勒隆制药公司 | 2022-12-23 | — | — | CN | claimed |
| EP-4100431-A1 | VARIANT ACTRIIB PROTEINS AND USES THEREOF | Acceleron Pharma Inc. (US) | 2022-12-14 | — | — | EP | claimed |
| US-11485737-B2 | Diaryl substituted 5,5-fused ring compounds as C5aR inhibitors | CHEMOCENTRYX, INC. (US) | 2022-11-01 | — | — | US | claimed |
| WO-2022219089-A1 | POLYMERIC MICROPARTICLES FOR THE LOCAL TREATMENT OF CHRONIC INFLAMMATORY DISEASES | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2022-10-20 | — | — | WO | claimed |
| CN-115209953-A | Compositions and methods for reducing ischemia reperfusion injury | 嘉安生物治疗有限责任公司 | 2022-10-18 | — | — | CN | claimed |
| US-20220307028-A1 | COMPOSITIONS AND METHODS FOR MITIGATION OF ISCHEMIC REPERFUSION INJURY | JAAN BIOTHERAPEUTICS, LLC | 2022-09-29 | — | — | US | claimed |
| WO-2022198264-A1 | TREATMENT OF INFLAMMATORY DISEASES | DIMERIX BIOSCIENCE PTY LTD (AU) | 2022-09-29 | — | — | WO | claimed |
| EP-4048398-A1 | COMPOSITIONS AND METHODS FOR MITIGATION OF ISCHEMIC REPERFUSION INJURY | Jaan Biotherapeutics, LLC (US) | 2022-08-31 | — | — | EP | claimed |
| US-20220152031-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. | 2022-05-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220152031-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GLS, ATP6V1B1, PDXK | CCR2 3685/4885CYP3A4 353/4885CYP2C9 643/4885 |
| US-20260007778-A1 | METHODS FOR TREATING AND DIAGNOSING BLINDING EYE DISEASES | AGER, ALDH1A2, RBP1 | CCR2 1297/4885CYP3A4 3874/4885CYP2C9 3774/4885 |
| US-11485737-B2 | Diaryl substituted 5,5-fused ring compounds as C5aR inhibitors | C5AR1, C5AR2, C3AR1 | CCR2 334/4885CYP3A4 1831/4885CYP2C9 1202/4885 |
| US-20250352511-A1 | METHODS OF TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH ATRASENTAN | REN, AGT, FRS2 | CCR2 336/4885CYP3A4 4075/4885CYP2C9 4021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.